Cozaar XQ Re-examination Study (MK-0954-349)

Organon and Co669 enrolled

Overview

This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.

Study Type

OBSERVATIONAL

Enrollment

669

Conditions

Hypertension

Interventions

amlodipine/losartanDRUG

amlodipine/losartan (COZAAR XQ) prescribed according to the current local label

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Participant with essential hypertension * Participant who is treated with COZAAR XQ within local label for the first time Exclusion criteria: * Participant who is treated with COZAAR XQ before contract and out of enrollment period * Participant who has a contraindication to COZAAR XQ according to the local label

Outcomes

Primary Outcomes

Number of participants with any adverse experience

Time frame: Up to 14 days after last treatment

Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator

Time frame: At 8 weeks after first treatment

Secondary Outcomes

Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator

Time frame: At 24 weeks after first treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.